SAB Biotherapeutics
SABS
48 hedge funds and large institutions have $136M invested in SAB Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 7 closing their positions.
200% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 7
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
141% more capital invested
Capital invested by funds: $56.3M → $136M (+$79.6M)
41% more funds holding
Funds holding: 34 → 48 (+14)
192.84% less ownership
Funds ownership: 269.17% → 76.34% (-193%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$7.05M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.87M |
| 3 |
PA
Perceptive Advisors
New York
|
+$2.64M |
| 4 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$2.15M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.87M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.14M |
| 3 |
Renaissance Technologies
New York
|
-$162K |
| 4 |
VF
Virtu Financial
New York
|
-$40K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
-$38.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Renaissance Technologies
New York
| – | -$162K | -80,840 | Closed |
|
|
VF
52
Virtu Financial
New York
| – | -$40K | -19,982 | Closed |
|
|
53
Kovitz Investment Group Partners
Chicago,
Illinois
| – | -$38.6K | -19,201 | Closed |
|
54
Dimensional Fund Advisors
Austin,
Texas
| – | -$31.7K | -15,781 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | -$3.14K | -1,560 | Closed |
|
SABS Hedge Fund Activity: Q4 2025 in Review
48 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2025, worth a combined $136M — up 141% from $56.3M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new SABS positions and 7 closed out — a net gain of 14 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Blackstone Inc, opening a new position worth an estimated $7.05M. The largest seller was BVF Inc, exiting entirely with an estimated $1.87M sold.
- 48 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2025, up from 34 in Q3 2025.
- Funds reported $136M of SAB Biotherapeutics stock for Q4 2025, up 141% quarter-over-quarter.
- 21 funds opened new SAB Biotherapeutics positions in Q4 2025 and 7 closed out, a net change of +14 holders.
- The largest SAB Biotherapeutics buyer in Q4 2025 was Blackstone Inc, an estimated $7.05M added.
- The largest SAB Biotherapeutics seller in Q4 2025 was BVF Inc, an estimated $1.87M sold.
Based on aggregated 13F filings for Q4 2025.